You are here: Industry Insights > Anifrolumab

News List

Anifrolumab Shows Benefit in Patients with Systemic Lupus Erythematosus americanpharmaceuticalreview
June 04, 2021
A new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and ...
Anifrolumab Improves Response at 52 Weeks in Lupus drugs
December 23, 2019
For patients with systemic lupus erythematosus (SLE), anifrolumab is associated with improved response at 52 weeks versus placebo ...
AstraZeneca’s SLE drug performs well in Phase III trial pharmaceutical-technology
September 03, 2019
AstraZeneca has announced anifrolumab met the primary endpoint of the Phase III Tulip trial studying 373 systemic lupus erythematosus (SLE) patients.
Potential New Lupus Treatment Effectively Reduced Disease Activity in Trial americanpharmaceuticalreview
September 03, 2019
The Lupus Research Alliance has announced a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study.
Anifrolumab Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
September 03, 2018
AstraZeneca and MedImmune announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE).